Compare
Foghorn Therapeutics Inc. vs Bioharvest Sciences Inc. vs Cue Biopharma, Inc. vs Celularity Inc
| Latest fiscal year | Foghorn Therapeutics Inc. FHTX | Bioharvest Sciences Inc. BHST | Cue Biopharma, Inc. CUE | Celularity Inc CELU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $30.91M | $34.51M | $27.47M | $26.55M |
| Revenue growth (YoY) | +36.8% | +37.0% | +195.7% | -51.0% |
| Gross margin | n/a | 59.3% (computed) | n/a | 24.4% (computed) |
| Operating margin | -279.5% | -16.2% | -96.7% | -230.9% |
| Net margin | -240.3% | -32.3% | -96.9% | -345.4% |
| Net income | -$74.28M | -$11.13M | -$26.60M | -$91.72M |
| EPS (Diluted) | -$1.18 | n/a | -$0.28 | -$3.59 |
| Operating cash flow | -$86.10M | -$7.23M | -$21.69M | -$13.25M |
| Free cash flow | -$86.15M | -$9.58M | -$21.86M | n/a |
| Cash & equivalents | $80.88M | $23.02M | $27.14M | $6.17M |
| Total assets | $198.10M | n/a | $42.21M | $107.33M |
| Total liabilities | $306.60M | n/a | $15.78M | $145.39M |
| Shareholders' equity | -$108.50M | $25.45M | $26.43M | -$38.06M |
| Return on year-end equity | n/a | -43.8% | -100.6% | n/a |
| Shares outstanding | 56.66M | n/a | 96.62M | 28.84M |
Revenue, most recent five fiscal years
| Fiscal year | Foghorn Therapeutics Inc. | Bioharvest Sciences Inc. | Cue Biopharma, Inc. | Celularity Inc |
|---|---|---|---|---|
| Latest | $30.91M Ended 2025-12-31 | $34.51M Ended 2025-12-31 | $27.47M Ended 2025-12-31 | $26.55M Ended 2025-12-31 |
| 1 year earlier | $22.60M Ended 2024-12-31 | $25.19M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $54.22M Ended 2024-12-31 |
| 2 years earlier | $34.16M Ended 2023-12-31 | $12.67M Ended 2023-12-31 | $5.49M Ended 2023-12-31 | $22.77M Ended 2023-12-31 |
| 3 years earlier | $19.23M Ended 2022-12-31 | n/a | $1.25M Ended 2022-12-31 | $17.98M Ended 2022-12-31 |
| 4 years earlier | $1.32M Ended 2021-12-31 | n/a | $14.94M Ended 2021-12-31 | $21.34M Ended 2021-12-31 |